Pneumonia

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

Retrieved on: 
Friday, December 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Multiple myeloma, Lymphocytopenia, Fever, Bispecific monoclonal antibody, NYSE, Cytokine release syndrome, PFE, European Medicines Agency, Rash, European Commission, Pneumonia, Upper respiratory tract infection, CRS, Risk, Febrile neutropenia, Fatigue, EMA, Civil service commission, Patient, Sepsis, Thrombocytopenia, Probability, Periodic breathing, Appetite, CHMP, B-cell maturation antigen, Injection site reaction, Committee, Neutropenia, Diarrhea, Nausea, Arthralgia, RRMM, Anemia, BCMA, Immunotherapy, Hypokalemia, Urinary tract infection, Inc., HIV disease progression rates, Vaccine, Pharmaceutical industry, Pfizer, Nature Medicine

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).
  • "More than 50,000 Europeans are diagnosed with multiple myeloma each year, and too often, they face relapse and treatment resistance,” said Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President, Pfizer.
  • The conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
  • This authorization follows the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation for a conditional marketing authorization on October 12, 2023.

Carbapenem Market Research Report 2023-2030: Analysis by Drug Class (Meropenem, Imipenem, Ertapenem), and Application (UTI, Blood Stream Infections, Pneumonia) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 28, 2023
General Health, Pharmaceutical, Health, USFDA, Fungal infection, Research, Urinary tract infection, Prevalence, Market, Developed country, Infection, ICU, Meropenem, Patient, Carbapenem, Death, USD, UTI, COVID-19, Bacteria, AMR, American Lung Association, Growth, MEM, Pfizer, Pharmaceutical industry, Antibiotics, Ertapenem, Application, Pneumonia, Imipenem

The "Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global carbapenem market size is expected to reach USD 5.24 billion by 2030., exhibiting a CAGR of 4.78% from 2023 to 2030.
  • In May 2023, Antabio initiated its Phase I trial by administering the initial dose of antibiotic therapy to healthy volunteers for hospital-acquired infections.
  • Based on drug class, the meropenem segment dominated the market in 2022, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains.

AHF Calls for China's Full Transparency on Spike in Respiratory Illnesses

Retrieved on: 
Monday, November 27, 2023
Biotechnology, AIDS, Other Health, Health, General Health, Healthcare Reform, Pharmaceutical, Other Policy Issues, Public Safety, Infectious Diseases, Public Policy, Government, Lancet, World Health Organization, Disclosure, Pneumonia, Century, WHO, Coronavirus, History, AHF, AIDS Healthcare Foundation, COVID-19, Press, Infection, Associated, SARS-CoV-2, SARS, Pharmaceutical industry

Following the Associated Press reporting that the World Health Organization requested that China provide more data on a “potentially worrying spike in respiratory illnesses and clusters of pneumonia in children” publicly, AIDS Healthcare Foundation expresses concern today and urges China to be transparent and cooperate with the WHO unequivocally.

Key Points: 
  • Following the Associated Press reporting that the World Health Organization requested that China provide more data on a “potentially worrying spike in respiratory illnesses and clusters of pneumonia in children” publicly, AIDS Healthcare Foundation expresses concern today and urges China to be transparent and cooperate with the WHO unequivocally.
  • “China has a history of a lack of disclosure of pertinent epidemiological data dating back to the SARS outbreak in 2002 and more recently with COVID-19.
  • The world cannot risk the repeat of a deadly infectious disease outbreak – we urge China to be transparent and cooperate with the WHO fully by releasing all data it has on respiratory illness cases in the country immediately,” said AHF President Michael Weinstein.
  • “The novel coronavirus pandemic was made incalculably worse because the world did not have a global public health framework based on transparency, accountability, and cooperation.

XEOMIN® (incobotulinumtoxinA) receives three new therapeutic indications in Australia

Retrieved on: 
Wednesday, November 22, 2023
Health, Consumer, Neurology, Children, Pharmaceutical, Biotechnology, Disease, Physician, Drooling, Brain, Nerve, Hope, Spasticity, Therapy, Pneumonia, Incidence, Neurotoxin, Choking, Social isolation, Risk, UMN, TGA, Spasm, Patient, Therapeutic Goods Administration, Stroke, Dehydration, Rehabilitation, Trial of the century, Motor disorder, Survivor, Disability, Saliva, Cerebral palsy, Skin, CP, Dietary supplement, Hypersalivation

This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market.

Key Points: 
  • This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market.
  • Additionally, XEOMIN ® is now approved for the treatment of pediatric spasticity of the upper and lower limb in children.
  • Until recently, only oral medications were approved for the treatment of sialorrhea, and these were associated with a number of systemic side effects.
  • The degree of disability may however differ among individuals, depending on symptoms intensity, number of involved body parts, and concomitant disorders.

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Retrieved on: 
Friday, November 17, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Online, NDC, Glass, Food, Recall, Pathology, Pneumonia, Completeness, NTRK, Literature, Immunosuppression, Central Time Zone, Patient, Probability, Fungal infection, Blood, Knowledge, Letter, Pharmacy, Pharmaceutical industry, Auction, Medical device, Dietary supplement, Bayer

Bayer is voluntarily recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level.

Key Points: 
  • Bayer is voluntarily recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level.
  • The product is being recalled due to microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing.
  • To date, Bayer has not received any adverse events related to this recall.
  • Bayer has engaged Qualanex to manage the recall of the product down to the consumer level.

Six Native American Nations Represented on the 2024 OneLegacy Donate Life Rose Parade® Float, Woven Together: The Dance of Life

Retrieved on: 
Thursday, November 16, 2023
Entertainment, Philanthropy, Other Entertainment, Family, Other Health, Health, Consumer, General Health, Foundation, Pneumonia, Kidney, Pancreas, Hopi, Transplant, Memory, Knowledge, Diet, Dance, Kidney disease, Choctaw Nation of Oklahoma, Heart, Metaphor, Butterfly Dance, Kickapoo people, Roger Hawkins (drummer), Communication, Chickasaw Nation, Okanogan County, Washington, Eye, The Dance of Life, Beauty, Kidney failure, Intraparenchymal hemorrhage, History, Culture, Liver failure, Partnership, Nation, Southwestern United States, American Nations, Air force, Liver, Rain, Injury, Medical device, Pharmaceutical industry, Dentistry, Life, Native

The 2024 OneLegacy Donate Life float, Woven Together: The Dance of Life will honor six Native American nations and their rich cultural heritage on New Year’s Day.

Key Points: 
  • The 2024 OneLegacy Donate Life float, Woven Together: The Dance of Life will honor six Native American nations and their rich cultural heritage on New Year’s Day.
  • For many tribes, dancing was an important method of communication, and the history of Native American dance is rich and meaningful.
  • Like most Hopi ceremonies, the Butterfly Dance is a petition for rain, good health and long life for all living things.
  • “We are very honored and proud to have our culture represented on the 2024 OneLegacy Donate Life float,” said Timothy Nuvangyaoma, Chairman of the Hopi Tribe.

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Status: Authorised

Retrieved on: 
Monday, December 18, 2023
Mantle cell lymphoma, Anatomy, Select, Urine, ATC, Protein kinase inhibitor, Neutrophil, Anemia, BTK, Pneumonia, MCL, International, INN, Disease, Language, Tablet, EMA, Patient, IIA, Marketing, Medical Subject Headings, Diarrhea, Neutropenia, Cancer, Infection, Bruise, Growth, Mouth, Fatigue, Urinary tract infection, Chemotherapy, Instrumentation, Vaccine, Pharmaceutical industry, Medicinal plants, Medical device, Medical imaging, Online shopping, Bookkeeping, Medicine, Lymphoma, Pirtobrutinib

Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021.

Key Points: 
  • Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021.
  • Treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
  • Treatment should be continued until the disease gets worse or the patient gets unacceptable side effects.
  • Jaypirca : EPAR - Medicine overview
    Product information
    Jaypirca : EPAR - Product information
    This medicine’s product information is available in all official EU languages.

The Association of American Indian Physicians Launches Campaign Aimed at Increasing Influenza and Shingles Vaccinations Among American Indian and Alaskan Natives

Retrieved on: 
Friday, November 10, 2023
Native American, Other Consumer, Health, Consumer, General Health, Pharmaceutical, Shingles, Television, Research, RSV, Pneumonia, Alaska Natives, Physician, Risk, Radio, Vaccination, Multimedia, Patient, Pregnancy, Pharmacy, FDA, Social media, Statistics, Death, CDC, Antibody, Family, PSAS, Hospital, Respiratory syncytial virus, Vaccine

The Association of American Indian Physicians (AAIP), a national nonprofit working to improve the health of American Indian and Alaskan Native (AI/AN) communities, is partnering with the Centers for Disease Control (CDC) to encourage increased influenza and shingles vaccination rates among AI/AN individuals.

Key Points: 
  • The Association of American Indian Physicians (AAIP), a national nonprofit working to improve the health of American Indian and Alaskan Native (AI/AN) communities, is partnering with the Centers for Disease Control (CDC) to encourage increased influenza and shingles vaccination rates among AI/AN individuals.
  • We’re grateful to partner with the CDC in this important endeavor.”
    According to the CDC , flu and pneumonia rank within the top 10 leading causes of death among American Indians.
  • “American Indian and Alaskan Natives face a higher risk for health complications from the flu,” president of AAIP, Dr. Lukejohn Day (Oglala Lakota) said.
  • In addition to increasing flu and shingles vaccination rates, AAIP will also offer resources for families concerned with the respiratory syncytial virus or RSV.

Olympic and World Champion Swimmer Maggie Mac Neil: "I understand the real fear of not being able to take a deep breath"

Retrieved on: 
Wednesday, December 6, 2023
Smoke, Paris Olympics, COPD, Next Generation, Breast, Way, Research, Depression, Respiratory disease, Education, RSV, LHF, Conditional sentence, Pneumonia, Ambassador, Shock, RSVP, Gold, Asthma, Gift, Long-term care, Prostate cancer, Lung cancer, Death, Survivor, Maggie Mac Neil, Hospital, Life, Fossil fuel, Medical device, Pharmaceutical industry, Poultry farming, Tobacco, Smoking

non-smoker have in common with elite Canadian athlete Maggie Mac Neil, who will defend her gold medal and world record in the 100m butterfly at the Paris Olympics next summer?

Key Points: 
  • non-smoker have in common with elite Canadian athlete Maggie Mac Neil, who will defend her gold medal and world record in the 100m butterfly at the Paris Olympics next summer?
  • If you are worried about your breathing; if you are struggling to breathe, seek help from a healthcare professional.
  • There is a treatment out there for you, and the Lung Health Foundation is there to guide and support you."
  • The flu and pneumonia consistently remain in the top 10 leading causes of death in Canada.

New Trends in Veterinary Medicine for 2024 Include Groundbreaking Treatments for America's Most Popular Pets: Cats, Frenchies and Bearded Dragons

Retrieved on: 
Wednesday, December 6, 2023
Diet, World's fair, Pet, CAE, Texas A&M University, Cat, Reptile, The Show of Shows, Organization, Face, Hiatal hernia, Pneumonia, Diabetes, Tail, Disease, Risk, American Veterinary Medical Association, Mortality, Expo Hall, Patient, Diplomate of National Board, Frenchie, Veterinary medicine, Snoring, FDA, Animal, DVM, Humidity, MythBusters, University, Health, Veterinarian, Diagnosis, Learning, Doctor of Philosophy, Internal medicine, VMX, Dog, Education, Pharmaceutical industry, Animal husbandry

ORLANDO, Fla., Dec. 6, 2023 /PRNewswire/ -- Breakthrough drugs that can save the lives of thousands of diabetic cats, new approaches to help veterinarians and pet owners recognize and treat illnesses unique to French bulldogs, and how to better care for bearded dragons, America's most popular pet reptile, are just a sample of the more than 800 continuing education sessions that will be offered at the 41st annual Veterinary Meeting & Expo (VMX). Presented by the North American Veterinary Community (NAVC), VMX is the largest global veterinary conference and sets the direction each year for the $104 billion animal health industry. This forum for the latest advances and innovations in animal health will be held January 13 -17, 2024 in Orlando, Florida.

Key Points: 
  • This forum for the latest advances and innovations in animal health will be held January 13 -17, 2024 in Orlando, Florida.
  • "The global conference attracts the most distinguished veterinary leaders who will share and teach exciting breakthroughs taking place today across the industry.
  • VMX 2024 will look at new medications, many designed specifically for animals, and how technology is transforming how we diagnose and treat animals.
  • It's a very exciting and promising time to be in veterinary medicine."